| Natalizumab significantly improved NeuroTrax global cognitive score over 2 years of treatment, regardless of whether patients were treatment-naive or were previously treated with other disease-modifying therapies. |
| Numerical improvements were observed for all seven individual cognitive domains from baseline to 2 years. |
| These results indicate that some aspects of cognitive impairment can be reduced in patients with multiple sclerosis treated with natalizumab. |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.